Cargando…

Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control

Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance...

Descripción completa

Detalles Bibliográficos
Autores principales: Velikova, Tsvetelina V., Kabakchieva, Plamena P., Assyov, Yavor S., Georgiev, Tsvetoslav А.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455209/
https://www.ncbi.nlm.nih.gov/pubmed/34557550
http://dx.doi.org/10.1155/2021/7297419
_version_ 1784570626128740352
author Velikova, Tsvetelina V.
Kabakchieva, Plamena P.
Assyov, Yavor S.
Georgiev, Tsvetoslav А.
author_facet Velikova, Tsvetelina V.
Kabakchieva, Plamena P.
Assyov, Yavor S.
Georgiev, Tsvetoslav А.
author_sort Velikova, Tsvetelina V.
collection PubMed
description Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance between pro and anti-inflammatory cytokines, anticytokine treatments might represent an additional therapeutic option for T2D patients. This review focuses on existing evidence for antihyperglycemic properties of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents (anti-TNF-α, anti-interleukin-(IL-) 6, -IL-1, -IL-17, -IL-23, etc.). Emphasis is placed on their molecular mechanisms and on the biological rationale for clinical use. Finally, we briefly summarize the results from experimental model studies and promising clinical trials about the potential of anticytokine therapies in T2D, discussing the effects of these drugs on systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity.
format Online
Article
Text
id pubmed-8455209
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84552092021-09-22 Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control Velikova, Tsvetelina V. Kabakchieva, Plamena P. Assyov, Yavor S. Georgiev, Tsvetoslav А. Biomed Res Int Review Article Type 2 diabetes (T2D) is one of the most common chronic metabolic disorders in adulthood worldwide, whose pathophysiology includes an abnormal immune response accompanied by cytokine dysregulation and inflammation. As the T2D-related inflammation and its progression were associated with the balance between pro and anti-inflammatory cytokines, anticytokine treatments might represent an additional therapeutic option for T2D patients. This review focuses on existing evidence for antihyperglycemic properties of disease-modifying antirheumatic drugs (DMARDs) and anticytokine agents (anti-TNF-α, anti-interleukin-(IL-) 6, -IL-1, -IL-17, -IL-23, etc.). Emphasis is placed on their molecular mechanisms and on the biological rationale for clinical use. Finally, we briefly summarize the results from experimental model studies and promising clinical trials about the potential of anticytokine therapies in T2D, discussing the effects of these drugs on systemic and islet inflammation, beta-cell function, insulin secretion, and insulin sensitivity. Hindawi 2021-09-13 /pmc/articles/PMC8455209/ /pubmed/34557550 http://dx.doi.org/10.1155/2021/7297419 Text en Copyright © 2021 Tsvetelina V. Velikova et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Velikova, Tsvetelina V.
Kabakchieva, Plamena P.
Assyov, Yavor S.
Georgiev, Tsvetoslav А.
Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
title Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
title_full Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
title_fullStr Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
title_full_unstemmed Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
title_short Targeting Inflammatory Cytokines to Improve Type 2 Diabetes Control
title_sort targeting inflammatory cytokines to improve type 2 diabetes control
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455209/
https://www.ncbi.nlm.nih.gov/pubmed/34557550
http://dx.doi.org/10.1155/2021/7297419
work_keys_str_mv AT velikovatsvetelinav targetinginflammatorycytokinestoimprovetype2diabetescontrol
AT kabakchievaplamenap targetinginflammatorycytokinestoimprovetype2diabetescontrol
AT assyovyavors targetinginflammatorycytokinestoimprovetype2diabetescontrol
AT georgievtsvetoslava targetinginflammatorycytokinestoimprovetype2diabetescontrol